RxDoctor Payments Data

Melony Malloy

Psychiatric/Mental Health · Raleigh, NCNPI 1033673736

Payments from drug & device makers

$2,271in general payments, 2019–2025

Across 85 payments — averaging $26.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$415
  • Alkermes, Inc.$365
  • Teva Pharmaceuticals USA, Inc.$224
  • Vanda Pharmaceuticals Inc.$221
  • Braeburn Inc.$193
  • Neurocrine Biosciences, Inc.$167
  • plus $685 from 9 others

What the payments were for

  • Food & beverage$2,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,271 in reported general payments places this provider in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,993
Medicare patients
13
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl35$52,502
RexultiBrexpiprazole25$47,435
Lurasidone Hcl40$4,398
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$4,107
Atomoxetine Hcl18$1,451
Aripiprazole35$786
Quetiapine Fumarate54$672
Methylphenidate Hcl61$620
Divalproex Sodium12$486
Clomipramine Hcl11$484
Gabapentin31$463
Lamotrigine74$433
Mirtazapine36$395
Clonazepam44$391
Trazodone Hcl65$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$114$52,50235 claims
Otsuka America Pharmaceutical, Inc.Rexulti$415$47,43525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →